<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In order to further explore low dose chemotherapy for high risk <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), low dose Ara-C and oral <z:chebi fb="0" ids="42068">idarubicin</z:chebi> (LAI) were given to 33 patients of 24-84 (median 66) years with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (12 patients), refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (13 patients), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with contraindications to intensive chemotherapy (8 patients) </plain></SENT>
<SENT sid="1" pm="."><plain>Patients received 1 to 4 cycles of Ara-C 10 mg/m2 q 12 h s.c. inject. on days 1-14 and <z:chebi fb="0" ids="42068">idarubicin</z:chebi> 20 mg/m2/d orally days 3, 4, 5 </plain></SENT>
<SENT sid="2" pm="."><plain>Three Three patients attained complete remission, four patients partial remission and one patient minor response, whereas 11 patients succumbed to early mortality from <z:mp ids='MP_0001914'>hemorrhage</z:mp> (two patients) and/or <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (10 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Three of 13 patients with heavily pretreated refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> went into remission compared to 3/12 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 1/8 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and contraindications against intensive treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Median duration of CR is 102 (70-488 +) days </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-two of 33 patients developed grade 4 hematological toxicity requiring platelet transfusions </plain></SENT>
<SENT sid="6" pm="."><plain>The non-hematologic toxicity was acceptable </plain></SENT>
<SENT sid="7" pm="."><plain>LAI provides a standardized therapeutic option especially for heavily pretreated patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>